Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Financial report summary
?Management Discussion
- Research and development expense was $12.09 million for the year ended December 31, 2019, compared to research and development expense of $25.16 million for the same period in 2018, representing a decrease of $13.07 million or 51.9%. The substantial decrease was mainly because the Company accelerated the research and development of Abexinostat and the launch of clinic trials in the second half of year 2018. As the Company started phase 3 clinic trials, the cost increased significantly. However, the Company encountered cashflow restraint after the Merger, it slowed down the Clinical trials in the US and switched the focus to China since the cost of the Clinical trials is substantially lower than those in US and Europe.